Abstract
Background: Major depression is a debilitating, sometimes fatal disorder, deteriorating the quality of life and well-being. Escitalopram showed highly selective and dose-dependent inhibitory activity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are the first-line drugs to manage major depressive disorder (MDD).
Objective: The objective of this study is to explore the therapeutic potential of escitalopram, a clinically approved drug to manage MDD and panic disorders.
Methods: It emphasizes comparative and clinical trial studies with several pharmacological targets reviewed from the data available on PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations.
Results: To highlight the clinical efficacy, safety, recent development, and stable formulation of escitalopram with an increased bioavailability profile. Evidence-based on the available clinical and pharmacoeconomic data, escitalopram represents an effective first-line treatment option for MDD patients.
Conclusion: The present review highlights the placebo-controlled clinical studies and the recent development that can be helpful for further research perspectives.
Keywords: Escitalopram, citalopram, MDD, SSRIs, SNRIs, clinical trials.
[http://dx.doi.org/10.2165/00023210-200317050-00004] [PMID: 12665392]
[http://dx.doi.org/10.1007/s00213-002-1364-z] [PMID: 12719960]
[http://dx.doi.org/10.1016/j.euroneuro.2004.08.008] [PMID: 15695064]
[http://dx.doi.org/10.1016/S0028-3908(03)00138-2] [PMID: 12842122]
[http://dx.doi.org/10.1038/sj.npp.1300686] [PMID: 15702136]
[http://dx.doi.org/10.2165/00003495-200565160-00013] [PMID: 16266205]
[http://dx.doi.org/10.1016/S0006-3223(01)01145-3] [PMID: 11543737]
[http://dx.doi.org/10.2165/00023210-200620090-00010] [PMID: 16953656]
[http://dx.doi.org/10.1111/j.1471-4159.2004.02835.x] [PMID: 15606893]
[http://dx.doi.org/10.1124/mol.105.018507] [PMID: 16434615]
[http://dx.doi.org/10.1007/s00213-004-1865-z] [PMID: 15160261]
[http://dx.doi.org/10.1007/s00213-006-0666-y] [PMID: 17235610]
[http://dx.doi.org/10.1016/S0149-2918(08)80047-1] [PMID: 18691982]
[http://dx.doi.org/10.1097/00004850-200205000-00001] [PMID: 11981349]
[http://dx.doi.org/10.4088/JCP.v63n0410] [PMID: 12000207]
[http://dx.doi.org/10.1097/01.yic.0000074988.54339.7c] [PMID: 12817155]
[PMID: 21206792]
[http://dx.doi.org/10.1097/00004850-200505000-00002] [PMID: 15812262]
[http://dx.doi.org/10.1007/s00213-010-1822-y] [PMID: 20340011]
[http://dx.doi.org/10.1016/j.clinthera.2007.11.014] [PMID: 18158074]
[http://dx.doi.org/10.1017/S146114571000115X] [PMID: 20875220]
[http://dx.doi.org/10.3325/cmj.2010.51.61] [PMID: 20162747]
[http://dx.doi.org/10.1185/030079906X115513] [PMID: 16834832]
[http://dx.doi.org/10.1097/01.yic.0000194377.88330.1d] [PMID: 16528138]
[http://dx.doi.org/10.1002/da.20222] [PMID: 17149753]
[http://dx.doi.org/10.1185/030079906X167273] [PMID: 17288677]
[http://dx.doi.org/10.2165/00044011-200727070-00005] [PMID: 17563128]
[http://dx.doi.org/10.1185/030079907X210732] [PMID: 17559755]
[http://dx.doi.org/10.4088/JCP.v65n0906] [PMID: 15367045]
[http://dx.doi.org/10.1159/000078225] [PMID: 15179022]
[http://dx.doi.org/10.1097/01.JGP.0000240823.94522.4c] [PMID: 17586783]
[http://dx.doi.org/10.4088/JCP.v67n1115] [PMID: 17196058]
[http://dx.doi.org/10.1185/03007990802622726] [PMID: 19210149]
[http://dx.doi.org/10.3390/jcm8101640]
[http://dx.doi.org/10.1016/j.sxmr.2017.07.002] [PMID: 28778697]
[http://dx.doi.org/10.1080/00926230590513474] [PMID: 16020143]
[http://dx.doi.org/10.2147/PPA.S22495] [PMID: 23271894]
[http://dx.doi.org/10.1111/j.1742-1241.2007.01335.x] [PMID: 17394446]
[PMID: 32122847]
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.089] [PMID: 28673858]
[http://dx.doi.org/10.3390/pharmaceutics13060891] [PMID: 34208460]
[http://dx.doi.org/10.1007/s12325-010-0073-y] [PMID: 20878372]
[http://dx.doi.org/10.1080/14786419.2018.1552698] [PMID: 30663358]
[http://dx.doi.org/10.1038/srep08902] [PMID: 25754735]